Bottom Line Summary
Statins for Primary Prevention (HOPE-3)
HOPE-3: Statin Therapy for Primary Prevention in Individuals at Intermediate Risk of Cardiovascular Disease Events
October 10, 2016
The Bottom Line:
In an adherent population of patients who were at intermediate cardiovascular risk at baseline (10% 10-year risk), daily statin treatment was associated with a reduction in cardiovascular outcomes, and a small increase in cataract surgery and muscle symptoms. Patients of African descent represented only a small proportion of the population studied.
Download PDF